Product Catalog

Tristemic

Treatment against Anaplasmosis and Piroplasmosis

for bovine, equine, ovine, caprine, canine and swine

 

Formula:

Each 100 mL contains:

Imidocarb Dipropionate 12 g

Excipients q.s.ad. 100 mL

 

Indications

For treatment, control and prevention of Anaplasmosis and Prioplasmosis. Diseases caused by hemoparasites associated to protozoan and rickettsias susceptible to imidocarb dipropionate.

 

Target species:

Bovine, equine, ovine, caprine, canine and swine.

 

Withdrawal period:

Meat: Do not slaughter animal for human consumption up to 28 days after the last application.

Milk: Do not administer to lactation animal intended for human consumption.

 

Administration route:

Parenteral, by subcutaneous or intramuscular route, according to the indications for each specie.

 

Dosage:

Bovine:

Piroplasmosis – Babesiosis: 2,1mg/kg, (equivalent to 1 ml every 40 kg of weight) S/C or I/M, repeating the dosage with an interval of 14 days between doses. Anaplasmosis: 2.5 mL /100 kg, S/C or I/M, repeating the dosage with an interval of 14 days between doses.

Equine:

Babesiosis caused by: B. equi: 1 mL every 20 kg of weight, repeating the dose 4 times, with an interval of 24 or 48 hours; if it is necessary apply a second dosage 2 weeks after the first one.

B. caballi: 1 mL/24 kg of weight I/M, if it is necessary repeat the treatment with an interval of 72 hrs and 2 weeks after.

Goat and ovines:

Babesiosis: 1 mL every 70 kg of weight, I/M or S/C; repeating the dosage with an interval of 14 days.

Canine:

Babesiosis: 1 mL every 12 kg of weight, I/M or S/C; Erlichiosis and Hepatozoonosis: 1 mL every 16 kg weight, I/M or S/C, in two doses (14 days interval). S/C route is recommended in this specie, diluting the product to administer in saline serum.

Swine:

1 mL every 16 kg weight, S/C, repeating the dosage with an interval of 14 days.

It is recommended to perform a syntomatological support treatment for all the species.

Categories: , , , , Tag:
Description

Treatment against Anaplasmosis and Piroplasmosis

for bovine, equine, ovine, caprine, canine and swine

 

Formula:

Each 100 mL contains:

Imidocarb Dipropionate 12 g

Excipients q.s.ad. 100 mL

 

Indications

For treatment, control and prevention of Anaplasmosis and Prioplasmosis. Diseases caused by hemoparasites associated to protozoan and rickettsias susceptible to imidocarb dipropionate.

 

Target species:

Bovine, equine, ovine, caprine, canine and swine.

 

Withdrawal period:

Meat: Do not slaughter animal for human consumption up to 28 days after the last application.

Milk: Do not administer to lactation animal intended for human consumption.

 

Administration route:

Parenteral, by subcutaneous or intramuscular route, according to the indications for each specie.

 

Dosage:

Bovine:

Piroplasmosis – Babesiosis: 2,1mg/kg, (equivalent to 1 ml every 40 kg of weight) S/C or I/M, repeating the dosage with an interval of 14 days between doses. Anaplasmosis: 2.5 mL /100 kg, S/C or I/M, repeating the dosage with an interval of 14 days between doses.

Equine:

Babesiosis caused by: B. equi: 1 mL every 20 kg of weight, repeating the dose 4 times, with an interval of 24 or 48 hours; if it is necessary apply a second dosage 2 weeks after the first one.

B. caballi: 1 mL/24 kg of weight I/M, if it is necessary repeat the treatment with an interval of 72 hrs and 2 weeks after.

Goat and ovines:

Babesiosis: 1 mL every 70 kg of weight, I/M or S/C; repeating the dosage with an interval of 14 days.

Canine:

Babesiosis: 1 mL every 12 kg of weight, I/M or S/C; Erlichiosis and Hepatozoonosis: 1 mL every 16 kg weight, I/M or S/C, in two doses (14 days interval). S/C route is recommended in this specie, diluting the product to administer in saline serum.

Swine:

1 mL every 16 kg weight, S/C, repeating the dosage with an interval of 14 days.

It is recommended to perform a syntomatological support treatment for all the species.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Tristemic”

Your email address will not be published. Required fields are marked *